15 Prince Arthur Avenue
Toronto, ON M5R 1B2
Canada
416-922-3460
https://www.antibethera.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 11
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Daniel Marcel Legault J.D., L.L.B. | Pres, CEO, Sec. & Director | 550,02k | N/A | 1958 |
Mr. Alain Wilson M.B.A., MBA | Chief Financial Officer | 154,06k | N/A | N/A |
Mr. Scott Curtis C.F.A., M.Eng | Chief Operating Officer | 218,89k | N/A | N/A |
Dr. David James Vaughan Ph.D. | Chief Devel. Officer | 300,31k | N/A | 1950 |
Dr. Joseph Stauffer D.O., M.B.A. | Chief Medical Officer | 819,8k | N/A | 1966 |
Dr. Ana Stegic | Exec. Director of Clinical Operations | 190,31k | N/A | N/A |
Ms. Christina Cameron B.B.A. | VP of Investor Relations | N/A | N/A | N/A |
Mr. Philip Stern | VP of Communications | N/A | N/A | N/A |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Antibe Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.